anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
A polylactide in a purified state, which meets the requirements of  - the colour strengths of reference solutions B2 - B9 of the brown colour test of the European Pharmacopoeia, 2nd       Edition (1980) part I, Section V, 6.2 and - containing one or more metals in cationic form, the metal ion(s) having a concentration of at most 10 ppm.   The polylactide is especially suitable for use as microparticles or implants, and contains preferably a hydrophilic drug, like octreotide or a lipophilic drug like bromocriptine. The metal ion is preferably Sn&lt;++&gt;, derived from the catalyst used to prepare the polylactide, e.g. the tin (II) salt of 2-ethyl-hexanoic acid. The purified polylactides may be prepared by contacting a solution of the impure polylactide with a matrix having on its surface carboxylic groups, e.g. active charcoal, and isolating the purified polymer from the eluate. The isolation step may further include ultrafiltration. The polylactide preferably contains glycolide units and preferably has a mean molecular weight of 10,000 to 200,000 and a polydispersity of 1.2 to 3.0.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a deodorizing article for removing hircismus.  &lt;P&gt;SOLUTION: The hircismus preventing article is obtained by finding that the use of a plant-based polyphenol (e.g. flavonoid or anthocyanin) and vegetative lipids prevents Staphylococcus being a causative bacterium of hircismus from living. The polyphenol is obtained by extracting cereal grain (including fermented grain) containing a polyphenol with ethanol. The gel article, the paste article and the patch article are produced by mixing the hircismus preventing article with lipid etc. The extract is mixed with ethanol or water, antisepticized and packed into a mist vessel to give a mist product.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain the subject tablet capable of lasting the effect for sufficient time with good feeling in use and withstanding long-time use by including xylitol, erythritol and ethyl cellulose into a sustained release tablet having adhesive layer and non-adhesive layer to oral mucous membrane. SOLUTION: This sustained release tablet is obtained by including (A) xylitol and/or erythritol, (B) ethyl cellulose into a sustained release tablet having adhesive layer and non-adhesive layer to oral mucous membrane and preferably further formulating (C) a hydrophobic nonionic surfactant having &lt;=9 HLB (e.g. hydrophobic sugar fatty acid ester) therewith. The component A content is 20-95 wt.% in non-adhesive layer and 0-70 wt.% in adhesive layer. The component B content is preferably &gt;=1% in the formulated layer. The content ration (weight ratio) of the component B to the component C is preferably 10:1 to 1:10.
Methods and systems to facilitate the collaborative development, discovery and implementation of evidence-based, clinical pathways are disclosed. Clinicians, medical professionals or researchers, may use the Platform 105 in multiple implementation, such as integrated with a third-party system like an EHR 104 to build and find clinical pathways through a graphical interface, creating relational data records between steps in pathways. Further, users of the Platform 105 may be able to associate relevant content such as published evidence, supplemental content items (e.g., videos, images, documents, ICD, CPT, SNOMED codes, and external web pages), and other associated pathways which reside in the system&#39;s database. Users of the Platform 105 may be able organize themselves into groups and networks to develop single pathways collaboratively. Users may be able to find specific pathways in the Platform 105 through semantic search, querying for relationships which exist inside of individual pathways. Search results may be generated for a variety of user driven data, both explicit and implicit.
The invention relates to externally applied paste for treating furunculous trauma infection. The paste is externally applied at a focus, directly reaches a sick part, and has three advantages that 1, the paste made of pure Chinese medicaments does not have toxic or side effect, adverse response or pain; 2, the paste has the characteristics of protecting the wound surface, resisting infection, detoxifying, clearing blood, removing stasis, eliminating necrotic tissues, promoting granulation, relieving pain, accelerating healing and the like; and 3, the paste is quick in acting and quick in response, can relieve pain in 30 minutes, and is wide in application range and convenient to use. The paste is prepared from 17 gouts of traditional Chinese medicines such as frankincense, myrrh, cutch and calomel according to methods of &#39;embodiments&#39; by selection. The paste can be used for easily reaching parts such as hands, feet, limbs and face and treating diseases caused by trauma infection such as zona impetigo, ringworm, herpes zoster, herpes, spider sore, chilblain and anal cyst. The paste can be used for treating in-nominated pyogenic infections, acne, epifolliculitis and the like. The paste has a unique curative effect on trauma infection such as postoperative wound un-healing, cuts, suppuration wounds caused by various reasons, seepage and various complications.
In a method of waving hair without the use of heat, the tresses of hair are each wrapped in a water-permeable pliable wrapping material carrying a substantially non-volatile water-soluble keratin-reducing composition containing essentially a mercaptan and an alkaline buffering material which is a hydroxy amine of the formula &lt;FORM:0860978/IV(c)/1&gt; in which X is hydrogen or an alkylol radical containing 1-3 carbon atoms, R1 and R11 are hydrogen, alkyl radicals containing 1-3 carbon atoms or alkylol radicals containing 1-3 carbon atoms and R111 is an alkylol radical containing 1-3 carbon atoms, excluding monoethanol amine; the tresses are then each wrapped about a curler and saturated with water so that the keratin-reducing composition is dissolved out of the wrapping material into the tress, the action of the composition on the hair subsequently being neutralized.  The mercaptan may be a mercapto alkanoic acid such as mercapto-acetic acid, mercapto propionic acid, mercapto butyric acid or mercapto caproic acid or a water-soluble salt thereof, e.g. sodium or potassium thioglycolate, monoethanolamine thioglycolate, b -mercapto iso butyric acid, thiohydracrylic acid, b mercapto-n-butyric acid, a -mercapto caproic acid or thiolactic acid, or mixtures thereof, and the sheets of wrapping material preferably carry an amount of mercaptan equivalent to from .003-.020 grams of thioglycolic acid per square inch of sheet.  The amount of alkaline buffering material used is preferably such that, when the composition is in solution and in contact with the hair, the pH value is 8,5-10,0.  The keratin-reducing composition may also contain a water-soluble disulphide of the mercaptan or a water-soluble salt thereof, lanolin, lanolin derivatives, perfumes, wetting agents, dyes, binders and plasticizers.  The water permeable pliable wrapping material may be cloth or paper, preferably cloth made from purified cotton or paper made from purified flax, provided if necessary with a plurality of perforations to increase its water permeability and is preferably 0,005-0,0005 inch thick before impregnation and long enough either to extend the entire length of the hair tresses or only to cover the ends of the hair tresses in the manner of &#34;end wraps.&#34; The wrapping material may be impregnated with an aqueous solution of the keratin-reducing composition and dried to a moisture content between 2 and 10% by weight.  The action of the hair of the mercaptan in the keratin-reducing composition may be neutralized by bromates, perborates or hydrogen peroxide or by the action of air alone. U.S.A. Specifications 2,719,814 and 2,719,815 are referred to.
PURPOSE:To provide a transcutaneous absorbefacient composed of a specific benzylsulfoxide derivative and effective in promoting the permeation and absorption of a drug through the skin. CONSTITUTION:The objective transcutaneous absorbefacient is composed of a compound of formula I (R is &gt;=6C hydrocarbon group; X is H, alkyl, alkenyl, halogen, NO2, acyl, NH2, acylamino, OH, carboxyl, alkoxycarbonyl or alkoxy). The compound is used in the form of tincture, ointment, cream, tape, etc., together with the drug to be administered. The amount of the compound in the preparation is 0.1-50wt.%, preferably 1-20wt.%. The compound of formula I can be easily produced by reacting a benzene derivative of formula II (Y is halogen, tosyloxy, etc.) with a thiol compound of formula RSH in the presence of a base and oxidizing the resultant benzylsulfide derivative of formula III with an oxidizing agent.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for delivering nucleic acid into cells, and a vector effective for delivering a polynucleotide, i.e. nucleic acid-containing microparticles having a size suitable for phagocytosis, into phagocytes without spoiling nucleic acid integrity.  &lt;P&gt;SOLUTION: A microparticle preparation comprising a polymer substrate and a nucleic acid expression vector is provided. The polymer substrate includes one or more synthetic polymers having solubility in water of less than about 1 mg/L. At least about 90% of the microparticles have a diameter less than about 100 micrometers. The nucleic acid is either RNA at least 50% of which is in the form of closed circles, or circular DNA plasmid molecules at least 50% of which are supercoiled.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
One or more organs of a living organism, preferably a warm-blooded animal, are artificially stimulated by irradiation, by chemical and like stimulants, by substantially reducing oxygen absorption by a tourniquet, or by subjection to low temperature and, from the organs so treated, or from body fluids circulating therethrough, substantially protein-free growth-regulating preparations are extracted by known chemical methods including a protein removal step. The growth-regulating preparations comprise nucleic acid derivatives, amino acids and polypeptides, and may be used in the treatment of degenerative diseases, such as thyroid diseases, leukaemia, nephrosis and X-ray ulcers.  The stimulation induces in the parenchema or mesenchema of the organ a state of unnatural activity which, it is stated, is to be regarded as a state of at least temporary mutation. In a modification, tissue from a stimulated organ is subjected to tissue cultivation. The stimulation may be intense irradiation as from radium, or by X-ray, ultra-violet, infra-red and heat radiation, electron and other elementary particle bombardment, or ultrasonic waves.  It may be by the incorporation of chemical stimulants which, as exemplified include fluorescent dyes, various drugs, inorganic materials, vaccines, sera, protein decomposition products and disinfectants.  Radio-active materials may be employed alone or with other of the chemical stimulants.  Examples include (1) the kidneys of a cow are irradiated by deep X-ray and blood circulating in the renal veins is removed to be worked up, (3) a dyestuff is injected into a pig which is then irradiated by ultra-violet.  The urine and skin are worked up; (4) indian ink is injected into a cow daily for about 14 days, the blood, the spleen and the thymus being worked up; (7) the blood circulation in a dog&#39;s leg is interrupted by tourniquet, the blood being later removed and worked up; (8) cultivated hen-egg heart tissue is irradiated by light and the nutrient solution worked up.
PROBLEM TO BE SOLVED: To obtain a tip care or a makeup composition for protecting lips from drying and for preventing the formation of cracks and/or chaps, by adding acexamic acid as an active care reagent to a specific fat phase. SOLUTION: This composition is obtained by adding (A) acexamic acid as an active care reagent to (B) a fat phase containing an oil selected from an oil of a hydrocarbon base containing &gt;=4 carbon atoms, a silicone oil, a fluorinated oil and their mixture. The amount of the component A is preferably 0.05-10%, more preferably 0.1-5% based on the total weight of the composition. The component A exists in a liberated form or a salt form, especially in a zinc salt form. The composition preferably contains a hydroxylated oil. A castor oil, isostearyl lactate, diisostearyl malate, octyldodecanol, etc., are preferably used as the hydroxylated oil.
1515540 4 - Amino - trans - decahydroquinoline derivatives LABAZ 24 Nov 1976 [16 Dec 1975] 51507/75 Heading C2C Novel trans decahydroquinoline derivatives of the Formula I and pharmaceutically acceptable acid addition salts thereof, wherein R1 is alkyl, alkoxy, dialkylamino, a saturated heterocyclic ring attached through a ring nitrogen atom, an unsaturated heterocyclic group or an optionally substituted phenyl, R2 is alkyl, optionally substituted phenyl, naphthyl, unsaturated heterocyclic optionally substituted by alkyl, aralkyl, aralkenyl or alicyclic and R3 is alkyl substituted furyl, aralkyl, aralkenyl or a group where A is C 1-4 -alkylene, Y is oxygen, sulphur, carbonyl &gt; C = NOH, &gt;C = NNH 2 or sulphoxide or a group X R4 and R5 each are hydrogen, halogen, methyl, methoxy or acetyl and n is zero or 1, with the proviso that when n is zero, Y is carbonyl, where alkyl groups unless otherwise specified have 1 to 4 carbon atoms, may be prepared, when R 1 is other than dialkylamino or saturated heterocyclic group attached by a ring nitrogen atom and when R3 is a group II, Y is other than hydroxyiminomethylene or hydrazonomethylene by reacting a compound III with R1COCl or (R1CO) 2 O or when R1 is dialkylamino or a saturated heterocyclic group attached by a ring nitrogen atom, and when R3 is a group II, Y is other than hydroxyiminomethylone or hydrazonomethylene by reacting a compound VI with an amine R1H, optionally followed by acid addition salt formation and/or reacting a carbonyl at Y with hydroxylamine or hydrazine to form a hydroxylimino methylene or a carbonyl hydrazonomethylene. Intermediates of the Formula III are prepared by reacting 4-oxo-trans-decahydroquinoline with an amine R2NH 2 and reducing the imine so formed to produce a compound VIII which is reacted with R3-Hal, where Hal is chlorine, bromine or iodine. When R3 is a group II and Y is carbonyl, the carbonyl group is protected with a group X and thereafter optionally hydrolysed. The isomers of the compound VIII are separated. Pharmaceutical compositions of the compounds I with the usual excipients show analgesic activity when administered orally, parenterally or rectally. The compounds I in which R1 is alkoxy also show antihypertensive action.
PURPOSE:To obtain a feline respiratory disease therapeutic agent exhibiting remarkable effects, even when administered through routes except veins, and capable of reducing the labor load of a person on the therapeutic duty and the economical load of an owner. CONSTITUTION:The characteristic of this feline respiratory organ disease therapeutic agent comprises containing as an active ingredient an interferon produced by a microorganismic or animal cell into which an HuIFN-related gene collected from cells originated from human has been introduced. The HuIFN can mainly be classified into three kind types consisting of HuIFN-alpha, HuIFN-beta and HuIFN-gamma on the basis of antigenicity. Only one kind type of the HuIFN may be used, or a combination of different kind types of the HuIFN may be used. Even when any HuIFN is used, it is desirable to use the HuIFN having as high specific activity as possible. When orally administered, a partially or wholly purified product having a specific activity of approximately 10&lt;5&gt; international units/mg of protein is desirable, and when parenterally administered, a purified product having a specific activity of approximately 10&lt;7&gt; international units/mg of protein is desirable.
PROBLEM TO BE SOLVED: To obtain an ultraviolet light screening agent having excellent ultraviolet light screening effect by using specific metal oxide ultrafine particulate powder narrow in band gap and high in safety and stability. SOLUTION: This ultraviolet light screening agent contains, as active ingredient, tungsten oxide (WO3 ) fine particulate powder 5-200nm (esp. 5-50nm) in average particle size (pref. coated with at least one kind of oxide selected from the group consisting of aluminum oxide, zirconium oxide and silicon oxide). Furthermore, the surface of the powder is pref. treated so as to be hydrophobicized or suppressed in activity. This ultraviolet light screening agent is useful as an active ingredient for preparations for external use for skin with natural finish and good usability, its amount to be incorporated in the preparation being pref. 0.1-60.0 (esp. 1.0-40.0)wt.% based on the preparation. This preparation for external use for skin is effective for screening ultraviolet light &lt;=400nm in wavelength (i.e., both UV-A and B).
Novel N-(2-aminocycloheptyl)-N-alkanoyl anilides of the formula &lt;IMAGE&gt; in which the substituents are defined in Claim 1, are prepared. These compounds are obtained by reacting 1,2-cycloheptene oxide with an R-benzylamine to give a trans-2-aminocycloheptanol. This latter is then converted with sodium hydride and methanesulphonyl chloride into a corresponding mesilate. The resulting mesilate is converted into a diamine by reaction with an aniline. The benzyl group is removed from this diamine from the 2-amino nitrogen by catalytic hydrogenation, and the resulting compound is then reacted with a C3- to C6-alkenyl chloride or bromide. Finally, the acyl radical is introduced by reaction with an appropriate acid anhydride, acid chloride or acid bromide. The compounds which are obtained can be used as antidepressants.
A laminate comprises a water-permeable material with a low friction surface in the presence of water the material being bonded by a water dispersible pressure sensitive adhesive to a repulpable tape which has the water dispersible pressure sensitive adhesive on both its surfaces. A device for controlled and prolonged release of an anthelmintic in a miminant comprises a resilient and flexible ethylene-vinyl acetate copolymer core sheet sandwiched between a pair of coextensive resilient films of the copolymer, the core sheet contg. 10-75% by wt. of a water-soluble morantel salt dispersed in it. The device has one or more circular macroperforations 0.5-10 mm in dia. symmetrically distributed across its face and extending through the films and core sheet. The dia. and arrangements of the macroperforations in relation to the thickness of the core sheet is selected to expose sufficient interior edge area of the sheet to give the required morantel release rate. The device is constrained in a rolled configuration by constraining means which are releasable in the animal&#39;s rumen, i.e. a laminate.
At least two publicly visible electronic displays are carried by a moving vehicle, each of which displays is positioned to be visible from a different external position relative to the vehicle. Separate messages can be displayed on the differently positioned displays. The selection of different messages for showing on different displays can be made as a function of differences between viewers who are likely to see the different displays. Such selections can be based on demographic information. The displays can include a side display that can better be seen from a position to the side of the vehicle, and a back display that can better seen from a position behind the vehicle. Messages considered more appropriate for pedestrians or more appropriate for rapid viewing can be shown on the side display, and those considered more appropriate for drivers behind the vehicle or for longer viewing can be shown on the back display. A plurality of such automotive vehicles each having multiple differently positioned signs can be used, with each vehicle carrying a communication interface. A central system can be used which includes one or more computers and communication interfaces. The central system&#39;s computers can enable on-line purchasing of the right to have a message displayed on selected ones of the differently positioned displays. In some embodiments a computer carried by a vehicle receives information about the vehicle&#39;s current location and successively displaying the names of different cross streets near vehicle&#39;s position on a back facing display.
PURPOSE:To prepare the titled drug soluble, dispersible and disintegrable rapidly at a specific pH, by coating a drug with a carboxymethylethylcellulose having a specific degree of neutralization. CONSTITUTION:The disintegrability of carboxymethylethylcellolose (CMEC) at 6.0 pH can be remarkably improved without lowering the disintegration resistance at &lt;=3.0-4.0 pH by partially neutralizing the CMEC. A drug is coated with a CMEC having a neutralization degree of 0.5-15% to obtain the objective enteric drug. The partial neutralization of CMEC can be carried out either by mixing a CMEC suspended in an aqueous coating liquid with a basic substance (e.g. alkali metal) of an amount to enable the neutralization of a part of the CMEC, or by mixing a salt of CMEC and basic substance with free CMEC. It can be administered in the form of tablet, capsule, pill, granule, powder, etc.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a patch package structure capable of stably retaining a physiologically active component of a patch while the patch is stored.  &lt;P&gt;SOLUTION: The patch package structure comprises the patch 1 and a package 51 for storing the patch 1. The patch 1 includes a support body 2 and an adhesive layer 3 disposed at least on one side of the support body 2. The package 51 includes a first package material 11, which includes an acrylonitrile resin layer 12, a moisture absorbent layer 13 disposed on the acrylonitrile resin layer 12, and a moisture impermeable layer 14 disposed on the moisture absorbent layer 13. The acrylonitrile resin layer 12 is located on the proximal side of the patch 1.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
The present invention relates to devices and methods of use thereof for making semiderivative voltammetric and chronoamperometric measurements of chemicals, e.g. neurotransmitters, precursors, and metabolites, in vitro, in vivo, or in situ. The invention relates to methods of diagnosing and/or treating a subject as having or being at risk of developing a disease or condition that is associated with abnormal levels of one or more neurotransmitters including, inter alia, epilepsy, diseases of the basal ganglia, athetoid, dystonic diseases, neoplasms, Parkinson&#39;s disease, brain injuries, spinal cord injuries, and cancer. The invention provides methods of differentiating white matter from grey matter using microvoltammetry. In some embodiments, regions of the brain to be resected or targeted for pharmaceutical therapy are identified using Broderick probes. The invention further provides methods of measuring the neurotoxicity of a material by comparing Broderick probe microvoltammograms of a neural tissue in the presence and absence of the material.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a safe and highly effective agent for preventing insulin resistance and for preventing metabolic syndrome.  &lt;P&gt;SOLUTION: The new, safe, and highly effective agents for preventing insulin resistance and for preventing metabolic syndrome that contain astaxanthin and/or an ester thereof as an active ingredient are provided. Even when a high-fat diet intake is continued, insulin resistance and subsequent hyperinsulinemia are suppressed by using the agent for preventing insulin resistance and the agent for preventing metabolic syndrome. Furthermore, suppression of fat degradation is thus inhibited and promotion of fat synthesis also is inhibited in adipose tissues, or glucose uptake into adipose tissues is inhibited, so that accumulation of fat within adipocytes is suppressed. Therefore, various diseases or symptoms having a relation to insulin resistance can be prevented or alleviated.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT